Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.33 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 3/20 | 0.32 |
| ▸ | DRD1 | P21728 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | PLEC | Q15149 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2228334 | 0.82 | RIPK1 (0.44) | RIPK1L3MBTL1MAPTNPSR1SSTR4 | |
| SCHEMBL2882181 | 0.81 | SSTR4 (0.31) | SSTR4 | |
| SCHEMBL1178456 | 0.81 | HTR2A (0.35) | SSTR4MEN1ALDH1A1KMT2ASLC6A4 | |
| SCHEMBL9194683 | 0.79 | HTR7 (0.46) | L3MBTL1MAPTSSTR4SSTR1HTT | |
| SCHEMBL2880031 | 0.78 | PKM (0.40) | L3MBTL1MAPTNPSR1MEN1KMT2A | |
| SCHEMBL1162275 | 0.77 | BCHE (0.35) | RIPK1DRD2ALDH1A1THRBTDP1 | |
| SCHEMBL2879878 | 0.76 | SCN4A (0.36) | SSTR4ALDH1A1SLC6A4 | |
| SCHEMBL14486495 | 0.75 | SLC6A2 (0.45) | L3MBTL1MAPTNPSR1HTTMEN1 | |
| SCHEMBL2009535 | 0.75 | KDM4E (0.33) | L3MBTL1KMT2A | |
| SCHEMBL2882255 | 0.75 | SSTR4 (0.30) | L3MBTL1SSTR4TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183234-B2 | Tricyclic guanidine derivatives as sodium-proton exchange inhibitors | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2012-05-22 | — | — | US | disclosed |
| US-7834001-B2 | N-(10,10-Dioxo-10,11-dihydro-5-oxa-10-lambda*6*-thia-dibenzo[a.d]cycloheptene-8-carbonyl)-guanidine; tumor necrosis factor inhibitors; sodium-proton exchange inhibitors for treatment of organ disorders associated with ischemia and reperfusion, cardiac arrhythmia, cardiac hypertrophy | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-11-16 | — | — | US | disclosed |
| US-20100267690-A1 | TRICYCLIC GUANIDINE DERIVATIVES AS SODIUM-PROTON EXCHANGE INHIBITORS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-10-21 | — | — | US | disclosed |
| US-7595315-B2 | Morpholine derivatives as norepinephrine reuptake inhibitors | ELI LILLY AND COMPANY (US) | 2009-09-29 | — | — | US | disclosed |
| EP-1515972-B1 | AMIDE SUBSTITUTED XANTHINE DERIVATIVES WITH GLUCONEOGENESIS MODULATING ACTIVITY | HOFFMANN LA ROCHE (CH) | 2009-05-13 | — | — | EP | disclosed |
| EP-1716126-B1 | MORPHOLINE DERIVATIVES AS NOREPINEPHRINE REUPTAKE INHIBITORS | LILLY CO ELI (US) | 2009-02-25 | — | — | EP | disclosed |
| US-20070299051-A1 | Tricyclic Guanidine Derivatives as Sodium-Proton Exchange Inhibitors | NICHOLAS PIRAMAL INDIA LIMITED. (IN) | 2007-12-27 | — | — | US | disclosed |
| EP-1812420-A1 | TRICYCLIC GUANIDINE DERIVATIVES AS SODIUM-PROTON EXCHANGE INHIBITORS | Nicholas Piramal India Limited (IN) | 2007-08-01 | — | — | EP | disclosed |
| US-20070060585-A1 | Morpholine derivatives as norepinephrine reuptake inhibitors | ELI LILLY AND COMPANY | 2007-03-15 | — | — | US | disclosed |
| US-7135475-B2 | Antidiabetic agents | HOFFMANN-LA ROCHE INC. (US) | 2006-11-14 | — | — | US | disclosed |
| EP-1716126-A1 | MORPHOLINE DERIVATIVES AS NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-11-02 | — | — | EP | disclosed |
| WO-2006051476-A1 | TRICYCLIC GUANIDINE DERIVATIVES AS SODIUM-PROTON EXCHANGE INHIBITORS | NICHOLAS PIRAMAL INDIA LIMITED (IN) | 2006-05-18 | — | — | WO | disclosed |
| WO-2005066144-A1 | MORPHOLINE DERIVATIVES AS NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-07-21 | — | — | WO | disclosed |
| EP-1515972-A1 | AMIDE SUBSTITUTED XANTHINE DERIVATIVES WITH GLUCONEOGENESIS MODULATING ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-23 | — | — | EP | disclosed |
| US-20040014766-A1 | Amide substituted xanthine derivatives | HOFFMANN-LA ROCHE INC. | 2004-01-22 | — | — | US | disclosed |
| WO-2003106459-A1 | AMIDE SUBSTITUTED XANTHINE DERIVATIVES WITH GLUCONEOGENESIS MODULATING ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014766-A1 | Amide substituted xanthine derivatives | GYS2, GLS2, PYGL | RIPK1 3026/4885L3MBTL1 3028/4885MAPT 3897/4885 |
| US-20070060585-A1 | Morpholine derivatives as norepinephrine reuptake inhibitors | SLC6A2, SLC18A2, SLC6A3 | RIPK1 4448/4885L3MBTL1 3566/4885MAPT 147/4885 |
| US-20100267690-A1 | TRICYCLIC GUANIDINE DERIVATIVES AS SODIUM-PROTON EXCHANGE INHIBITORS | ATP2A1, ATP2A3, KCNN4 | RIPK1 1626/4885L3MBTL1 1090/4885MAPT 4692/4885 |
| US-20070299051-A1 | Tricyclic Guanidine Derivatives as Sodium-Proton Exchange Inhibitors | ATP2A1, ATP2A3, KCNN4 | RIPK1 1626/4885L3MBTL1 1090/4885MAPT 4692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.